KSNW Wichita on MSN5mon
Rare ‘liger’ rescued from abandoned home near US border
The liger – a cross between a male lion and a ... the six deceased were members of La Linea and a Chihuahua-based cell of the ...
Piper Sandler sets $84 target on Merus stock, cites drug potential
Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...
Morningstar12d
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
Petosemtamab (MCLA-158: EGFR x LGR5 Biclonics®): Solid Tumors LiGeR-HN1 phase 3 trial in 1L PD-L1+ r/m head and neck squamous cell carcinoma (HNSCC) and LiGeR-HN2 phase 3 trial in 2/3L r/m HNSCC ...
Business Insider26d
Merus initiated with an Overweight at Piper Sandler
Piper expects additional Phase II data on the combo in 2025 to “significantly de-risk” the Phase III LiGeR-HN1 study ... 2035 in head and neck squamous cell carcinoma alone.
Business Insider21d
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
About LiGeR-HN1 LiGeR-HN1 ... About Head and Neck Cancer Head and neck squamous cell carcinoma (HNSCC) describes a group of cancers that develop in the squamous cells that line the mucosal ...